Title21 Health Solutions has formed its first Advisory Committee to bring practical insight into the development of its software platform designed for cell and gene therapy (CGT) workflows. As the pace of CGT development accelerates, the company says it is essential that its technology evolves in step with the needs of the clinics, labs, and manufacturing sites working to deliver these complex treatments.

The new committee includes five professionals with expertise that spans drug development, clinical operations, and healthcare systems. The goal is to build a platform that meets the operational realities of this evolving field while supporting innovation and patient access.

“We’ve built Title21 around the idea that software should serve the people actually delivering care,” said Tony Pare, CEO of Title21. “This committee gives us a direct connection to the environments where cell and gene therapies are created, processed, and administered. Their input will be essential as we move forward.”

Among the new advisors is Dr. Stella Vnook, a biotech entrepreneur and former Merck executive. She currently leads Likarda, a company developing technologies that improve drug delivery for cell therapies. “Getting these therapies to work in the real world requires more than science—it requires systems that make the process reproducible, trackable, and patient-safe,” said Vnook. “Title21’s platform is addressing that, and I’m excited to help shape it.”

Also joining the committee is Dr. Elena Maryamchik, who directs the Cell Therapy Laboratory at Memorial Sloan Kettering Cancer Center. Her work focuses on the clinical logistics of cell therapy—from managing cellular products to ensuring chain of custody and quality control.

Jeff Liter brings extensive trial and commercialisation experience, having led more than 20 CGT clinical studies. He previously served as CEO of Luminary Therapeutics and B-MoGen Biotechnologies. “We’ve seen how software bottlenecks can slow progress,” said Liter. “What Title21 is doing—building tools to support speed without sacrificing compliance—is urgently needed.”

From Penn Medicine, both Robb Richards and Caitlin Cahill offer deep insight into healthcare delivery. Richards leads the institution’s Cell Therapy and Transplant program, while Cahill oversees blood, stem cell, and apheresis services. Both have firsthand experience integrating CGT products into large academic health systems, where regulatory demands and patient care need to be balanced.

“We’re grateful to these experts for lending their time and knowledge,” added Pare. “This is about building software that’s as advanced and reliable as the therapies it supports.”